Stock Data
$0.03 (0.18%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
HEALTH INFORMATION SERVICES
Simulations Plus Inc specializes in advanced software for drug discovery and development. With a focus on artificial intelligence and machine learning, it offers tools like GastroPlus for simulating drug absorption and interactions. Its portfolio also includes DDDPlus, MembranePlus, and a suite of mechanistic models such as DILIsym and NAFLDsym. Beyond software, Simulations Plus provides consulting in pharmacokinetics and regulatory submissions, serving industries from pharmaceuticals to cosmetics. Founded in 1996 and based in Lancaster, California, it's a key player in supporting the lifecycle of drug development.
Simulations Plus crushed EPS expectations by 29% and returned to GAAP profitability with a 7% revenue gain driven by 20% growth in services, positioning the biopharma software maker well ahead of its expected close with Altaris later this year.
Simulations Plus reports after the bell as FDA's Operation TrialBlazer puts biosimulation tools in regulatory spotlights—watch whether the software segment captures that momentum.
0 Articles
No articles found for Simulations Plus.
Our top personal finance-related articles today. Your wallet will thank you later.
